Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
|
The following article is a part of conference coverage from the American Association of Clinical Endocrinology Annual Meeting 2021: ENVISION, being held virtually from May 26 to May 29, 2021. The team at Endocrinology Advisor will be reporting on the latest news and research conducted by leading experts in the field. Check back for more from the AACE Annual Meeting 2021: ENVISION. |
The use of a digital therapeutics platform in people with obesity and metabolic syndrome can lead to a reduction in both weight and body mass index (BMI), thereby reducing risk for comorbidities, according to study results presented at the 30th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (ENVISION 2021).
Digital therapeutic platforms allow clinicians to deliver lifestyle-modification interventions remotely. These interventions have the potential to influence weight loss in people with obesity and metabolic syndrome through the delivery of evidence-based care even in settings that are resource-limited.
Researchers evaluated engagement of patients with the Wellthy CARE™ Digital Therapeutics (WDTx) Platform and effectiveness of the platform in influencing lifestyle modifications and enabling weight loss in patients with obesity and metabolic syndrome.
The WDTx Platform provides a 52-week lifestyle modification program focused on diet, physical activity, weight management, remote patient monitoring, glycemic control, and blood pressure control. The platform provides artificial intelligence-augmented healthcare tracking, evidence-backed content, and personalized health coach support.
The study participants (n=196; 19.4% women; mean age 46.1 years, baseline BMI of 23 kg/m2) used the WDTx Platform over a 52-week period. The investigators reported 418 average app interactions per user. Study participants with metabolic syndrome had an average of 734 app interactions per user.
Study participants who were considered high interactors — those in the highest quartile of engagement with the app — lost 3 kg of weight compared with those in the lowest quartile of interaction who lost 1.2 kg, representing a 2.5-times difference between quartiles.
The investigators saw a significant reduction in mean body weight among all WDTx platform users at the end of the program compared with measurement at baseline, as well as by category (overweight, obese I, and obese II) and among patients with metabolic syndrome.
“This study demonstrates the real-world effectiveness of the [WDTx] platform amongst people with obesity and metabolic syndrome,” the researchers concluded, adding that higher platform engagement led to both weight loss and BMI reduction and a subsequent reduction in comorbidity risk for these patient populations.
Disclosures: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
|
Visit Endocrinology Advisor‘s conference section for complete coverage from the AACE Annual Meeting 2021: ENVISION. |
Reference
Adhikary R, Kolwankar S, Verma R, et al. Real-world effectiveness of digital therapeutics towards achieving weight loss in people with obesity and metabolic syndrome. Presented at: 2021 AACE Virtual Annual Meeting, May 26-29, 2021.
